1 March 2025 - The March 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.

There are a few new/revised listings of note this month:

• Bevacizumab (Vegzelma) - new indications
• Atezolizumab (Tecentriq) - new indication
• Lanreotide acetate (Mytolac) - new indications
• Denosumab (Prolia) - restriction change (osteoporosis)

Read New Zealand Pharmaceutical Schedule update